China FDA issues 'user-friendly' guidance on medical device registration studies; waivers may prove a challenge
This article was originally published in SRA
The China Food and Drug Administration has for the first time issued guidance that explains how medical device makers should conduct clinical evaluations of the products they seek to register in China and in which cases they may obtain a clinical study waiver1.
You may also be interested in...
Medical device companies operating in China are still looking for clearer guidance that will help them make the most of the wide-ranging regulatory reforms introduced in the country since 2014.
New medicines under evaluation at the European Medicines Agency.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.